Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Carcinoma, Hepatocellular 17Stomach Neoplasms 8Colorectal Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Rectal Neoplasms 5Neoplasm Metastasis 4Triple Negative Breast Neoplasms 3Pancreatic Neoplasms 3Nasopharyngeal Carcinoma 3Esophageal Neoplasms 3Uterine Cervical Neoplasms 2Solid Tumor 2Recurrence 2Lung Neoplasms 2Esophageal Squamous Cell Carcinoma 2Endometrial Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Spinocerebellar Degenerations 1Small Cell Lung Carcinoma 1Resectable NSCLC 1Ovarian Neoplasms 1Neuroblastoma 1Neoplasms, Unknown Primary 1Neoplasms 1Metastatic Gastroesophageal Junction Adenocarcinoma 1Meningeal Carcinomatosis 1MSI-H 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

Gemcitabine 113130-nm albumin-bound paclitaxel 64Albumin-Bound Paclitaxel 43Fluorouracil 37Magnetic Resonance Spectroscopy 35pembrolizumab 34Irinotecan 34Taxes 33Specimen Handling 33Leucovorin 33Oxaliplatin 31Biopsy 22Cyclophosphamide 21Nivolumab 18fludarabine 16Radiosurgery 16Cisplatin 16Drug Therapy 15Capecitabine 12folfirinox 11durvalumab 11Radiotherapy 11irinotecan sucrosofate 10Ipilimumab 10Cetuximab 10Carboplatin 10Blood Specimen Collection 10olaparib 9Standard of Care 9dehydroftorafur 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × sintilimab × 1 year × Clear all
NCT06050317 2026-05-01

Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer

Shandong Cancer Hospital and Institute

Phase 2 Recruiting
25 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT06353646 2026-02-13

XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer

Peking Union Medical College Hospital

Phase NA Recruiting
28 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT05481476 2025-09-04

Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer

Sun Yat-sen University

Phase 2 Active not recruiting
32 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡